Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2006

View Archived Issues

ReGen and Metagenics enter commercialization agreement for Colostrinin

Archemix and Elan partner for aptamer therapeutics to treat autoimmune disease

Genzyme: Q2 progress report

Three studies show ACP-104 safe, well tolerated, with initial antipsychotic effect

PEP-005 Topical yields dose-dependent tumor clearance rates in nodular BCC

Abraxane begins phase I in Japan

Flurizan studied for Alzheimer's disease at U. of South Florida

Daiichi Sankyo and Lilly sign European agreement for Evista

Schering and Avid to develop diagnostic imaging agents for Alzheimer's disease

New phase I/II trial studies PXD-101 for inoperable hepatocellular cancer

Roche and Actelion collaborate on selective S1P1 receptor agonist

First patients complete follow-up in phase I/II study of BDM-E

CSL and Zenyth Therapeutics announce proposed merger

Tipifarnib feasible, active with doxorubicin and cyclophosphamide in breast cancer

TGN-255 shows potential as an anticoagulant in hemodialysis patients

Targeting 5-HT4 for cognitive and attention deficits in AD

In vitro pharmacological profile of F-15063 indicates antipsychotic potential

Positive pharmacological and safety profile of Hematide in preclinical studies

Novel calixarene-based antiangiogenic compounds show antitumor properties in vivo

Implanon, first FDA approved single-rod implantable contraceptive

Gemzar approved for use in ovarian cancer

New therapeutic agents for hematological disorders disclosed in recent Nissan patent

Recent patents report novel analgesic agents

New therapeutic agents for HCV infection imparted in recent Gilead patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...